Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintena...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 May 2019
|
| In: |
BMC cancer
Year: 2019, Jahrgang: 19 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-5600-x |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1186/s12885-019-5600-x
|
| Verfasserangaben: | Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1668738570 | ||
| 003 | DE-627 | ||
| 005 | 20230427221528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190708s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-019-5600-x |2 doi | |
| 035 | |a (DE-627)1668738570 | ||
| 035 | |a (DE-599)KXP1668738570 | ||
| 035 | |a (OCoLC)1341233093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Salwender, Hans |e VerfasserIn |0 (DE-588)1114928666 |0 (DE-627)869399993 |0 (DE-576)477578233 |4 aut | |
| 245 | 1 | 0 | |a Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 |b a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma |c Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt |
| 264 | 1 | |c 28 May 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.07.2019 | ||
| 520 | |a Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintenance treatment in an intensified treatment concept, including high dose melphalan (200 mg/m2), has resulted in increased CR rates, and is considered the standard of care for younger patients. Elotuzumab in combination with lenalidomide and dexamethasone has given better results as lenalidomide and dexamethasone alone in a phase III trial. The GMMG-HD6 trial will be the first phase III trial investigating the role of elotuzumab in combination with bortezomib, lenalidomide and dexamethasone (VRD) induction/consolidation and lenalidomide maintenance within a high dose concept. | ||
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Benner, Axel |d 1959- |e VerfasserIn |0 (DE-588)106584686X |0 (DE-627)81687221X |0 (DE-576)425536602 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Huhn, Stefanie |d 1982- |e VerfasserIn |0 (DE-588)1014984424 |0 (DE-627)705313190 |0 (DE-576)349876436 |4 aut | |
| 700 | 1 | |a Hundemer, Michael |d 1972- |e VerfasserIn |0 (DE-588)128390549 |0 (DE-627)372634001 |0 (DE-576)297117998 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Seidel-Glätzer, Andrea |e VerfasserIn |0 (DE-588)1190052709 |0 (DE-627)1668735849 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 19(2019) Artikel-Nummer 504, 11 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g extent:11 |a Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-019-5600-x |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190708 | ||
| 994 | |a 2019 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 27 |y j | ||
| 998 | |g 1190052709 |a Seidel-Glätzer, Andrea |m 1190052709:Seidel-Glätzer, Andrea |d 910000 |d 913000 |e 910000PS1190052709 |e 913000PS1190052709 |k 0/910000/ |k 1/910000/913000/ |p 15 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |e 910000PJ1025525140 |e 911500PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |p 14 | ||
| 998 | |g 128390549 |a Hundemer, Michael |m 128390549:Hundemer, Michael |d 910000 |d 910100 |e 910000PH128390549 |e 910100PH128390549 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 1014984424 |a Huhn, Stefanie |m 1014984424:Huhn, Stefanie |d 910000 |d 910100 |e 910000PH1014984424 |e 910100PH1014984424 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 910000 |d 910100 |d 50000 |e 910000PH139824995 |e 910100PH139824995 |e 50000PH139824995 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 106584686X |a Benner, Axel |m 106584686X:Benner, Axel |d 50000 |e 50000PB106584686X |k 0/50000/ |p 6 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1668738570 |e 3491888654 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Salwender, Hans","family":"Salwender","role":"aut","given":"Hans"},{"family":"Bertsch","display":"Bertsch, Uta","role":"aut","given":"Uta"},{"family":"Benner","display":"Benner, Axel","given":"Axel","role":"aut"},{"role":"aut","given":"Marc-Steffen","display":"Raab, Marc-Steffen","family":"Raab"},{"family":"Hillengaß","display":"Hillengaß, Jens","given":"Jens","role":"aut"},{"given":"Dirk","role":"aut","display":"Hose, Dirk","family":"Hose"},{"given":"Stefanie","role":"aut","display":"Huhn, Stefanie","family":"Huhn"},{"given":"Michael","role":"aut","display":"Hundemer, Michael","family":"Hundemer"},{"given":"Anna","role":"aut","family":"Jauch","display":"Jauch, Anna"},{"role":"aut","given":"Andrea","family":"Seidel-Glätzer","display":"Seidel-Glätzer, Andrea"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut","given":"Hartmut"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"28 May 2019","dateIssuedKey":"2019"}],"note":["Gesehen am 08.07.2019"],"title":[{"subtitle":"a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma","title_sort":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6","title":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6"}],"id":{"eki":["1668738570"],"doi":["10.1186/s12885-019-5600-x"]},"relHost":[{"pubHistory":["1.2001 -"],"note":["Gesehen am 22.05.20"],"origin":[{"publisher":"BioMed Central ; Springer","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisherPlace":"London ; Berlin ; Heidelberg"}],"title":[{"title_sort":"BMC cancer","title":"BMC cancer"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaBMC cancer","recId":"326643710","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2041352-X"],"issn":["1471-2407"],"eki":["326643710"]},"language":["eng"],"part":{"text":"19(2019) Artikel-Nummer 504, 11 Seiten","extent":"11","volume":"19","year":"2019"}}],"recId":"1668738570","name":{"displayForm":["Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt"]},"physDesc":[{"extent":"11 S."}]} | ||
| SRT | |a SALWENDERHRATIONALEA2820 | ||